Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Scientists discover new way to create human blood from adult skin

Scientists discover new way to create human blood from adult skin

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Rockwell Medical third quarter sales increases 4.1% to $14.7 million

Rockwell Medical third quarter sales increases 4.1% to $14.7 million

NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

Affymax receives $244,479.25 in funding under QTDP program

Affymax receives $244,479.25 in funding under QTDP program

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

GSK's Revolade receives Japanese approval for treatment of chronic ITP

GSK's Revolade receives Japanese approval for treatment of chronic ITP

AmerisourceBergen fiscal fourth quarter revenue increases 5.3% to $19.7 billion

AmerisourceBergen fiscal fourth quarter revenue increases 5.3% to $19.7 billion

Micronutrient Initiative receives $75 million to expand innovative nutrition programming

Micronutrient Initiative receives $75 million to expand innovative nutrition programming

ADVANCE Phase 3 study confirms clinical benefits of telaprevir regimen in patients with HCV infection

ADVANCE Phase 3 study confirms clinical benefits of telaprevir regimen in patients with HCV infection

Valeant, Kadmon enter strategic agreement for taribavirin and ribavirin

Valeant, Kadmon enter strategic agreement for taribavirin and ribavirin

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Clear guidelines needed for consistent diagnosis and treatment of childhood stroke

Clear guidelines needed for consistent diagnosis and treatment of childhood stroke

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Shield signs strategic commercialization agreement for ST10-021 iron therapy product

Shield signs strategic commercialization agreement for ST10-021 iron therapy product

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.